SCA Pharmaceuticals, LLC

SCA Pharmaceuticals, LLC is a specialized provider of sterile compounding services, focused on delivering high-quality pharmaceutical products, including sterile admixtures and pre-filled syringes, crucial for healthcare settings. Founded in 2010 in Little Rock, US, SCA Pharmaceuticals, LLC provides sterile compounding services under the FDA 503B outsourcing framework. The company was fully acquired by Excellere Partners and The Vistria Group in January 2021 for USD 125 mn. Scott Luce serves as CEO.

The company has engaged in three funding deals to date, with the latest being a Secondary Buyout that raised USD 125 mn, matching the total amount raised. SCA Pharmaceuticals specializes in a comprehensive range of sterile compounding services under the FDA 503B outsourcing framework. Its core offerings include high-quality sterile admixtures and pre-filled syringes, tailored for hospital and healthcare facility pharmacies, particularly in critical care, labor and delivery, anesthesia, and pain management. Licensed to operate in all 50 states, SCA Pharmaceuticals serves a wide client base of hospitals and healthcare facilities, continuously adapting its product catalog to meet their evolving medication needs.

SCA Pharmaceuticals generates revenue through the provision of its 503B compounded pharmaceuticals, primarily engaging in direct sales to hospitals and healthcare facilities. The company facilitates agreements for the supply of ready-to-use products, addressing drug shortages, and typically involves multi-year contracts that ensure a stable flow of essential medications. Its revenue model emphasizes customer service and quality assurance to maintain long-term relationships with healthcare providers. Following its acquisition in January 2021, SCA Pharmaceuticals plans to use the raised funds to expand its sterile pharmaceutical manufacturing sites in Windsor, Connecticut, and Little Rock, Arkansas.

The company is poised to accelerate its growth trajectory, with strategies focused on enhancing its product offerings and increasing its manufacturing capabilities to meet the rising demand in the healthcare sector.